smartOCT: a low-cost technology to detect and monitor glaucoma in outpatient and primary care centers
smartOCT:一种在门诊和初级保健中心检测和监测青光眼的低成本技术
基本信息
- 批准号:10579902
- 负责人:
- 金额:$ 39.07万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-05-01 至 2025-03-31
- 项目状态:未结题
- 来源:
- 关键词:AdultAffectAgreementAlgorithmic SoftwareAmbulatory CareAppointmentBlindnessCaringCellular PhoneClinicClinicalClinical ResearchCommunitiesDataDemocracyDetectionDeteriorationDevicesDiabetes MellitusDiagnosisDiseaseEarly treatmentEffectivenessEndocrinologyEthnic OriginEvaluationEyeFamilyGlaucomaHealthHealth FairsImageImaging TechniquesImprove AccessInsuranceLaboratoriesLatinoLie DetectionManualsMeasurementMeasuresModelingMonitorMorphologic artifactsMotionNatureOphthalmologistOphthalmologyOptic DiskOptic NerveOptical Coherence TomographyOutcomeOutpatientsPatientsPerformancePeripheralPersonsPharmacy facilityPhysiologic Intraocular PressurePilot ProjectsPopulation StudyPrevalencePrimary CarePrimary Open Angle GlaucomaQualitative MethodsQualitative ResearchRecording of previous eventsResearchResourcesRiskRisk FactorsRoleScanningServicesSignal TransductionSiteSystemTechnologyTelemedicineThickTimeTrainingTravelUnderserved PopulationVisionVisualizationWorkagedcostcost effectiveexperienceglaucoma testglobal healthhealth care qualityhealth care settingshealthy volunteerhigh resolution imaginghigh riskimaging systeminnovationinstrumentlight weightmodifiable risknew technologynoveloptical discoutpatient programspoint of careportabilitypreservationprimary care clinicprimary care providerprogramsprototyperetinal imagingretinal nerve fiber layerscreeningscreening programsensorsmartphone based devicestemtelehealthuser-friendly
项目摘要
ABSTRACT: Glaucoma is the leading cause of irreversible vision loss globally. Nearly 52.7 million people will
be affected in 2020, and that number will grow to ~79.8 million by 2040. The prevalence varies by ethnicity,
and the rates of undiagnosed primary open angle glaucoma are alarmingly high (50-85%) in white, black and
Latino patients. The challenge in glaucoma detection lies in the asymptomatic nature of its early stage:
damage to the optic nerve occurs in an unnoticeable manner that slowly deteriorates the peripheral vision. By
the time many patients seek evaluation, the disease has reached a late stage and it is a challenge to preserve
the limited remaining central vision. Importantly, early treatment to decrease intraocular pressure (IOP), the
only modifiable risk factor for glaucoma, can reduce the rate of progression by 50%, but large population-
based studies have confirmed that screening based on IOP is clinically ineffective.
Optical coherence tomography (OCT) is central technology for glaucoma screening in standard ophthalmology
services. However, the cost and size of clinical OCT systems limits access to the technology by underserved
populations, who are simultaneously more likely to be affected with glaucoma-inducing conditions (e.g.,
diabetes) and less likely to have access to adequate eye care, vision insurance and ability to travel for
additional appointments. The availability of low-cost, portable and user-friendly technologies that are
deployable in non-specialist outpatient settings (e.g., primary care clinics, endocrinology offices)
where high-risk patients present most often is a critical barrier to widespread implementation of
effective glaucoma screening programs.
We propose a new paradigm for OCT imaging – smartOCT – that leverages the small form factor and ubiquity
of smartphones (SPs) to yield a low-cost, lightweight, small-footprint device that facilitates capture, processing,
visualization and interpretation of OCT data in outpatient services. Our innovative strategy targets
comprehensive integration of OCT with the built-in sensors of smartphones to lower the critical barriers to
mass deployment of OCT in clinics. We will demonstrate the feasibility of this technology and clinical workflow
through the following specific aims: Aim 1) Finalize a smartOCT prototype for low-cost optic nerve imaging.
Aim 2) Confirm the repeatability of smartOCT and comparison to conventional OCT in a pilot clinical study (n =
60). Aim 3) Evaluate the preliminary effectiveness for outpatient services in a pilot study (n = 40) with primary
care. If successful, our work will suggest a clear path to broaden access to the OCT technology needed to
detect glaucoma and to inspire equip new paradigms and contexts for effective glaucoma screening (e.g.,
clinics, health fairs, telemedicine). Successful implementation of smartOCT technology will also blaze a trail for
the OCT research community to consider new form factors and new scanning mechanisms that can be
implicated to study other clinical diseases and/or used in other resource-limited contexts (e.g., global health).
摘要:青光眼是全球不可逆视力丧失的主要原因。近5270万人将
到2020年,这一数字将增长到约7980万。患病率因种族而异,
未诊断的原发性开角型青光眼的比率在白色、黑人和
拉丁裔病人。青光眼检测的挑战在于其早期阶段的无症状性质:
视神经的损伤以不明显的方式发生,其缓慢地恶化周边视觉。通过
当许多患者寻求评估时,疾病已经到了晚期,
有限的中央视觉。重要的是,早期治疗以降低眼内压(IOP),
青光眼的唯一可改变的危险因素,可以减少50%的进展率,但大的人群-
基于IOP的研究已经证实,基于IOP的筛查在临床上是无效的。
光学相干断层扫描(OCT)是标准眼科学中青光眼筛查的核心技术
服务然而,临床OCT系统的成本和尺寸限制了服务不足者对该技术的使用。
人群,他们同时更有可能受到脑卒中诱导条件的影响(例如,
糖尿病),更不可能获得足够的眼科护理,视力保险和旅行能力,
额外的任命。提供低成本、便携式和方便用户的技术,
可部署在非专科门诊设置中(例如,初级保健诊所、内分泌科诊所)
高风险患者最常出现的地方是广泛实施
有效的青光眼筛查计划。
我们提出了一种新的OCT成像模式- smartOCT -它利用了小尺寸和普遍存在的
智能手机(SP)的生产成本低,重量轻,占地面积小的设备,便于捕获,处理,
门诊服务中OCT数据的可视化和解释。我们的创新战略目标
OCT与智能手机内置传感器的全面集成,以降低
OCT在诊所的大规模部署。我们将证明这项技术和临床工作流程的可行性
通过以下具体目标:目标1)最终确定用于低成本视神经成像的smartOCT原型。
目的2)在初步临床研究中确认smartOCT的可重复性以及与传统OCT的比较(n = 10)。
60)。目的3)在一项初步研究(n = 40)中评价门诊服务的初步有效性,
在乎如果成功的话,我们的工作将为扩大OCT技术的使用提供一条清晰的道路,
检测青光眼并激发装备用于有效青光眼筛查的新范例和背景(例如,
诊所、健康博览会、远程医疗)。smartOCT技术的成功实施也将为
OCT研究界考虑新的形式因素和新的扫描机制,
涉及研究其它临床疾病和/或用于其它资源有限的环境(例如,全球健康)。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Audrey Kynsella Bowden其他文献
Audrey Kynsella Bowden的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Audrey Kynsella Bowden', 18)}}的其他基金
Smart-phone-integrated, non-invasive, depth-resolved optical spectroscopy for the detection of neonatal jaundice
用于检测新生儿黄疸的智能手机集成、非侵入性、深度分辨光谱
- 批准号:
10677538 - 财政年份:2022
- 资助金额:
$ 39.07万 - 项目类别:
Smart-phone-integrated, non-invasive, depth-resolved optical spectroscopy for the detection of neonatal jaundice
用于检测新生儿黄疸的智能手机集成、非侵入性、深度分辨光谱
- 批准号:
10346706 - 财政年份:2022
- 资助金额:
$ 39.07万 - 项目类别:
A whole-cortex fNIRS system to shine light on the problem of post-operative delirium
全皮质 fNIRS 系统可解决术后谵妄问题
- 批准号:
10373814 - 财政年份:2021
- 资助金额:
$ 39.07万 - 项目类别:
A whole-cortex fNIRS system to shine light on the problem of post-operative delirium
全皮质 fNIRS 系统可解决术后谵妄问题
- 批准号:
10495236 - 财政年份:2021
- 资助金额:
$ 39.07万 - 项目类别:
smartOCT: a low-cost technology to detect and monitor glaucoma in outpatient and primary care centers
smartOCT:一种在门诊和初级保健中心检测和监测青光眼的低成本技术
- 批准号:
10396115 - 财政年份:2021
- 资助金额:
$ 39.07万 - 项目类别:
smartOCT: a low-cost technology to detect and monitor glaucoma in outpatient and primary care centers
smartOCT:一种在门诊和初级保健中心检测和监测青光眼的低成本技术
- 批准号:
10186159 - 财政年份:2021
- 资助金额:
$ 39.07万 - 项目类别:
A Wearable Optical Imaging System for Daily Monitoring of Prefrontal Activity in ADHD
用于日常监测多动症患者前额叶活动的可穿戴光学成像系统
- 批准号:
10043220 - 财政年份:2020
- 资助金额:
$ 39.07万 - 项目类别:
相似海外基金
RII Track-4:NSF: From the Ground Up to the Air Above Coastal Dunes: How Groundwater and Evaporation Affect the Mechanism of Wind Erosion
RII Track-4:NSF:从地面到沿海沙丘上方的空气:地下水和蒸发如何影响风蚀机制
- 批准号:
2327346 - 财政年份:2024
- 资助金额:
$ 39.07万 - 项目类别:
Standard Grant
BRC-BIO: Establishing Astrangia poculata as a study system to understand how multi-partner symbiotic interactions affect pathogen response in cnidarians
BRC-BIO:建立 Astrangia poculata 作为研究系统,以了解多伙伴共生相互作用如何影响刺胞动物的病原体反应
- 批准号:
2312555 - 财政年份:2024
- 资助金额:
$ 39.07万 - 项目类别:
Standard Grant
How Does Particle Material Properties Insoluble and Partially Soluble Affect Sensory Perception Of Fat based Products
不溶性和部分可溶的颗粒材料特性如何影响脂肪基产品的感官知觉
- 批准号:
BB/Z514391/1 - 财政年份:2024
- 资助金额:
$ 39.07万 - 项目类别:
Training Grant
Graduating in Austerity: Do Welfare Cuts Affect the Career Path of University Students?
紧缩毕业:福利削减会影响大学生的职业道路吗?
- 批准号:
ES/Z502595/1 - 财政年份:2024
- 资助金额:
$ 39.07万 - 项目类别:
Fellowship
Insecure lives and the policy disconnect: How multiple insecurities affect Levelling Up and what joined-up policy can do to help
不安全的生活和政策脱节:多种不安全因素如何影响升级以及联合政策可以提供哪些帮助
- 批准号:
ES/Z000149/1 - 财政年份:2024
- 资助金额:
$ 39.07万 - 项目类别:
Research Grant
感性個人差指標 Affect-X の構築とビスポークAIサービスの基盤確立
建立个人敏感度指数 Affect-X 并为定制人工智能服务奠定基础
- 批准号:
23K24936 - 财政年份:2024
- 资助金额:
$ 39.07万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
How does metal binding affect the function of proteins targeted by a devastating pathogen of cereal crops?
金属结合如何影响谷类作物毁灭性病原体靶向的蛋白质的功能?
- 批准号:
2901648 - 财政年份:2024
- 资助金额:
$ 39.07万 - 项目类别:
Studentship
ERI: Developing a Trust-supporting Design Framework with Affect for Human-AI Collaboration
ERI:开发一个支持信任的设计框架,影响人类与人工智能的协作
- 批准号:
2301846 - 财政年份:2023
- 资助金额:
$ 39.07万 - 项目类别:
Standard Grant
Investigating how double-negative T cells affect anti-leukemic and GvHD-inducing activities of conventional T cells
研究双阴性 T 细胞如何影响传统 T 细胞的抗白血病和 GvHD 诱导活性
- 批准号:
488039 - 财政年份:2023
- 资助金额:
$ 39.07万 - 项目类别:
Operating Grants
How motor impairments due to neurodegenerative diseases affect masticatory movements
神经退行性疾病引起的运动障碍如何影响咀嚼运动
- 批准号:
23K16076 - 财政年份:2023
- 资助金额:
$ 39.07万 - 项目类别:
Grant-in-Aid for Early-Career Scientists